XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Megazyme Ltd And Subsidiary Megazyme Inc [Member]
Common Stock
Common Stock
Megazyme Ltd And Subsidiary Megazyme Inc [Member]
Additional Paid-in Capital
Additional Paid-in Capital
Megazyme Ltd And Subsidiary Megazyme Inc [Member]
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning Balance at May. 31, 2020 $ 725,177   $ 16,943   $ 249,221   $ (19,709) $ 478,722
Beginning Balance (in shares) at May. 31, 2020 105,892,000              
Exercise of options and share-based compensation expense $ 5,839   28   5,811      
Exercise of options and share-based compensation expense (in shares) 172,000              
Issuance of shares under employee stock purchase plan $ 668   3   665      
Issuance of shares under employee stock purchase plan (in shares) 18,000              
Net income $ 15,860             15,860
Other comprehensive income(loss) 4,002           4,002  
Ending Balance at Aug. 31, 2020 $ 751,546   16,974   255,697   (15,707) 494,582
Ending Balance (in shares) at Aug. 31, 2020 106,082,000              
Beginning Balance at May. 31, 2020 $ 725,177   16,943   249,221   (19,709) 478,722
Beginning Balance (in shares) at May. 31, 2020 105,892,000              
Net income $ 45,122              
Ending Balance at Feb. 28, 2021 $ 807,683   17,124   281,556   (14,841) 523,844
Ending Balance (in shares) at Feb. 28, 2021 107,022,000              
Beginning Balance at Aug. 31, 2020 $ 751,546   16,974   255,697   (15,707) 494,582
Beginning Balance (in shares) at Aug. 31, 2020 106,082,000              
Exercise of options and share-based compensation expense $ 9,343   64   9,279      
Exercise of options and share-based compensation expense (in shares) 406,000              
Net income $ 15,885             15,885
Other comprehensive income(loss) 621           621  
Ending Balance at Nov. 30, 2020 $ 777,395   17,038   264,976   (15,086) 510,467
Ending Balance (in shares) at Nov. 30, 2020 106,488,000              
Exercise of options and share-based compensation expense $ 11,030   62   10,968      
Exercise of options and share-based compensation expense (in shares) 386,000              
Issuance of shares under employee stock purchase plan $ 720   4   716      
Issuance of shares under employee stock purchase plan (in shares) 20,000              
Issuance of shares for Megazyme acquisition   $ 4,916   $ 20   $ 4,896    
Issuance of shares for Megazyme acquisition (in shares) 128,000              
Net income $ 13,377             13,377
Other comprehensive income(loss) 245           245  
Ending Balance at Feb. 28, 2021 $ 807,683   17,124   281,556   (14,841) 523,844
Ending Balance (in shares) at Feb. 28, 2021 107,022,000              
Beginning Balance at May. 31, 2021 $ 840,377   17,195   294,953   (11,375) 539,604
Beginning Balance (in shares) at May. 31, 2021 107,468,304              
Exercise of options and share-based compensation expense $ 1,839   1   1,838      
Exercise of options and share-based compensation expense (in shares) 6,000              
Issuance of shares under employee stock purchase plan $ 899   3   896      
Issuance of shares under employee stock purchase plan (in shares) 19,000              
Net income $ 17,077             17,077
Other comprehensive income(loss) (4,829)           (4,829)  
Ending Balance at Aug. 31, 2021 $ 855,363   17,199   297,687   (16,204) 556,681
Ending Balance (in shares) at Aug. 31, 2021 107,493,000              
Beginning Balance at May. 31, 2021 $ 840,377   17,195   294,953   (11,375) 539,604
Beginning Balance (in shares) at May. 31, 2021 107,468,304              
Net income $ 33,348              
Ending Balance at Feb. 28, 2022 $ 875,544   17,251   307,780   (22,439) 572,952
Ending Balance (in shares) at Feb. 28, 2022 107,818,159              
Beginning Balance at Aug. 31, 2021 $ 855,363   17,199   297,687   (16,204) 556,681
Beginning Balance (in shares) at Aug. 31, 2021 107,493,000              
Exercise of options and share-based compensation expense $ 7,316   44   7,272      
Exercise of options and share-based compensation expense (in shares) 275,000              
Net income $ 10,828             10,828
Other comprehensive income(loss) (8,031)           (8,031)  
Ending Balance at Nov. 30, 2021 $ 865,476   17,243   304,959   (24,235) 567,509
Ending Balance (in shares) at Nov. 30, 2021 107,768,000              
Exercise of options and share-based compensation expense $ 1,852   4   1,848      
Exercise of options and share-based compensation expense (in shares) 26,000              
Issuance of shares under employee stock purchase plan $ 977   4   973      
Issuance of shares under employee stock purchase plan (in shares) 24,000              
Net income $ 5,443             5,443
Other comprehensive income(loss) 1,796           1,796  
Ending Balance at Feb. 28, 2022 $ 875,544   $ 17,251   $ 307,780   $ (22,439) $ 572,952
Ending Balance (in shares) at Feb. 28, 2022 107,818,159